Aztreonam avibactam pharmacokinetics describes how the two components of this combination behave in the body after administration, including their absorption, distribution, exposure, elimination and relationship to pharmacodynamic targets.
Aztreonam is a beta-lactam antibacterial agent, while avibactam is a beta-lactamase inhibitor. Because both components contribute to the overall activity of the combination, understanding their individual pharmacokinetic profiles and the combined PK/PD relationship is important when evaluating dosing strategies.
Recent Phase 1 research published in 2026 found that the pharmacokinetic characteristics of aztreonam and avibactam in healthy Chinese participants were consistent with previous findings, with no clinically significant exposure differences compared with non-Chinese participants.
What Is the Pharmacokinetic Profile of Aztreonam Avibactam?
Aztreonam-avibactam is administered intravenously, and both components can be described using standard pharmacokinetic parameters such as:
- Cmax — maximum plasma concentration
- AUC — overall drug exposure
- Half-life — the time required for plasma concentration to decrease by approximately half during the terminal phase
- Clearance — the rate at which drug is eliminated from the body
- Volume of distribution — an estimate of how extensively the drug distributes outside the plasma
- Protein binding — the proportion of drug bound to plasma proteins
The current U.S. prescribing information reports relatively short terminal half-lives for both components and predominantly renal elimination.
Key pharmacokinetic characteristics
| Parameter | Aztreonam | Avibactam |
|---|---|---|
| Mean terminal half-life | 2.03 ± 0.69 h | 2.04 ± 0.52 h |
| Plasma protein binding | 38% | 8% |
| Volume of distribution at steady state | 21.4 ± 23 L | 37.8 ± 73 L |
| Clearance | 10.2 ± 22 L/h | 18 ± 39 L/h |
| Unchanged urinary excretion | 64.2–75.9% | 83.8–100% |
These values are from the U.S. prescribing information and describe pharmacokinetics under the studied clinical conditions; they should not be interpreted as universal values for every patient.
Aztreonam Avibactam Half-Life
The aztreonam avibactam half life is relatively short.
In the current U.S. prescribing information, the mean terminal half-life is approximately:
- 2.03 hours for aztreonam
- 2.04 hours for avibactam
The 2026 Phase 1 study provides additional context. After single dosing, mean half-life was approximately 1.89 hours for aztreonam and 2.00 hours for avibactam. After multiple dosing, aztreonam remained approximately 1.89 hours, while the reported terminal half-life for avibactam was 4.06 hours. The researchers noted that the difference for avibactam may reflect selection of the terminal phase and a multiphasic decline rather than a simple change in drug disposition.
Therefore, half-life values should always be interpreted in the context of the study design, sampling schedule and population.
How Is Aztreonam Avibactam Eliminated?
Renal elimination is an important part of the aztreonam avibactam pharmacokinetics profile.
The current U.S. prescribing information identifies renal excretion through glomerular filtration and tubular secretion as the major elimination route. Approximately 64.2% to 75.9% of an aztreonam dose and 83.8% to 100% of an avibactam dose were recovered unchanged in urine in the pharmacokinetic assessment described in the label.
This renal elimination helps explain why kidney function is an important consideration when evaluating exposure and dosing.
Renal Function and Drug Exposure
When renal function decreases, clearance of renally eliminated drugs can decrease as well.
For aztreonam-avibactam, this relationship is particularly relevant because both components are substantially eliminated through the kidneys.
The prescribing information therefore includes dose adjustments based on renal function. This is not simply a pharmacokinetic observation; it is directly relevant to maintaining appropriate drug exposure while reducing the risk of excessive accumulation.
This is also why aztreonam avibactam renal dosing should be considered separately from the broader pharmacokinetic discussion.
For detailed dosing information, see our article on aztreonam avibactam renal dosing.
What Is the Role of Drug Exposure?
Pharmacokinetics describes drug exposure, but exposure alone does not tell us whether an antibacterial regimen will be effective.
For beta-lactam antibiotics, the relationship between drug concentration and the organism’s MIC is particularly important.
The key concept is:
How long does the free drug concentration remain above the organism’s MIC during the dosing interval?
This is expressed as:
%fT > MIC
where:
- f = unbound/free drug
- T = dosing interval
- MIC = minimum inhibitory concentration
For aztreonam, time above MIC is an important pharmacodynamic measure.
Aztreonam Avibactam PK/PD
The pharmacodynamics of the combination are more complex than simply looking at aztreonam exposure.
Both components need to achieve their relevant pharmacodynamic targets.
Research used for dose selection identified:
- Aztreonam: 60% fT > MIC
- Avibactam: 50% fT > 2.5 mg/L
as joint PK/PD targets for the combination. These targets were derived from preclinical infection models and subsequently incorporated into probability-of-target-attainment analyses.
This is an important concept because avibactam does not function as the primary antibacterial component. Its role is to maintain sufficient exposure to inhibit relevant beta-lactamases and help preserve aztreonam activity.
Why Is Avibactam Exposure Important?
Avibactam’s PK/PD relationship differs from that of the partner antibiotic.
Experimental studies found that the efficacy of aztreonam in combination with avibactam was associated with the percentage of time aztreonam concentrations remained above the MIC.
For avibactam, the relevant relationship was the percentage of time its free concentration remained above a critical threshold concentration.
Studies identified approximately 2–2.5 mg/L as an important threshold range, with 2.5 mg/L used in subsequent PK/PD target development for aztreonam-avibactam.
This illustrates why simply comparing total AUC or Cmax between regimens does not fully describe the pharmacology of the combination.
Why Extended Infusion Matters
The pharmacokinetic profile also helps explain the use of prolonged intravenous infusion.
For time-dependent beta-lactam activity, maintaining drug concentrations above the relevant MIC for an adequate proportion of the dosing interval is important.
The current U.S. prescribing information describes administration of aztreonam-avibactam as a 3-hour intravenous infusion. It also reports minimal accumulation following repeated 3-hour infusions every 6 hours in patients with normal renal function.
The purpose of discussing prolonged infusion in PK/PD terms is not simply to say that “longer infusion is better.” Rather, infusion duration is one component of a dosing regimen designed to achieve the intended exposure profile.
What Did the 2026 Phase 1 Study Show?
A Phase 1 open-label study published in February 2026 evaluated aztreonam-avibactam pharmacokinetics in healthy Chinese participants after single and multiple intravenous doses. The study used the same fixed 3:1 aztreonam-to-avibactam ratio used in clinical development.
The researchers reported that the pharmacokinetic characteristics of both components were consistent with previous knowledge.
They also found no clinically significant differences in exposure between Chinese and non-Chinese participants included in the ethnic comparison.
After repeated dosing, median trough concentrations from Day 2 through Day 4 were similar, and the maximum concentrations were generally reached around the end of the 3-hour infusion.
Important limitation
This was a Phase 1 study in healthy participants.
Therefore, its findings help characterize pharmacokinetics but should not be interpreted as direct evidence of clinical efficacy in patients with severe resistant infections.
Aztreonam Avibactam PK/PD and MBL-Producing Bacteria
The PK/PD discussion becomes particularly relevant when considering resistant Gram-negative organisms.
Aztreonam is relatively stable against hydrolysis by metallo-beta-lactamases, while avibactam inhibits several susceptible serine beta-lactamases that may be co-produced by the same organism.
The pharmacological strategy therefore depends on maintaining adequate exposure to both components.
However, PK/PD target attainment does not automatically equal clinical cure.
Clinical outcome depends on additional factors including:
- organism susceptibility
- infection site
- bacterial burden
- host factors
- source control
- resistance mechanisms
- appropriate dosing
- achievement of drug exposure at the relevant infection site
A 2026 review notes that PK/PD evidence supports the pharmacological rationale of aztreonam-avibactam, while also emphasizing that clinical data specifically involving microbiologically confirmed MBL-producing infections remain limited.
Pharmacokinetics vs Pharmacodynamics: What’s the Difference?
These two terms are often confused.
Pharmacokinetics — PK
What the body does to the drug.
It includes:
- absorption
- distribution
- metabolism
- elimination
- concentration over time
Pharmacodynamics — PD
What the drug does in relation to its biological target.
For aztreonam-avibactam, this includes the relationship between antimicrobial exposure, MIC and beta-lactamase inhibition.
PK/PD
PK/PD connects the two.
It asks:
Does the drug exposure achieved by a dosing regimen reach the pharmacodynamic target associated with antibacterial activity?
This is one of the key concepts behind modern beta-lactam dose selection.
Aztreonam Avibactam Pharmacokinetics: Key Factors
| Factor | Why it matters |
|---|---|
| Renal function | Both components undergo substantial renal elimination |
| MIC | Determines the concentration threshold relevant to aztreonam activity |
| Free drug concentration | PK/PD targets use unbound drug exposure |
| Infusion duration | Influences the concentration-time profile |
| Dosing interval | Determines how exposure is maintained over time |
| Beta-lactamase production | Influences the role of avibactam |
| Infection characteristics | Can influence pharmacokinetic variability and target attainment |
What PK/PD Evidence Can—and Cannot—Tell Us
PK/PD studies are important for selecting and evaluating dosing regimens, but they have limitations.
PK/PD evidence can help explain:
- how drug concentrations change over time;
- why renal function affects exposure;
- which exposure parameters are associated with antibacterial activity;
- how dosing regimens can be evaluated;
- whether simulated populations are likely to achieve predefined targets.
PK/PD evidence cannot independently establish:
- clinical superiority over another antibiotic;
- clinical cure in every infection;
- activity against every resistant isolate;
- that every patient will achieve the same exposure;
- that laboratory susceptibility guarantees treatment success.
This distinction is particularly important when discussing highly resistant Gram-negative infections.
How PK/PD Connects With Aztreonam Avibactam Dosing
The dosing regimen is ultimately designed around maintaining adequate exposure of both components.
The pharmacokinetic principles discussed here connect directly with:
- dosing interval;
- infusion duration;
- renal dose adjustment;
- MIC;
- PK/PD target attainment.
For this reason, pharmacokinetics should be considered alongside—not instead of—clinical dosing guidance.
For more information, see our related guide on aztreonam avibactam dosage and administration.
Frequently Asked Questions
What is the half-life of aztreonam-avibactam?
The current U.S. prescribing information reports mean terminal half-lives of approximately 2.03 hours for aztreonam and 2.04 hours for avibactam under the described study conditions.
Is aztreonam-avibactam primarily eliminated by the kidneys?
Yes. Renal excretion is the major elimination route for both components, making renal function an important factor in exposure and dosing.
What is the main PK/PD target for aztreonam?
For the combination, dose-selection studies used 60% fT > MIC as the aztreonam PK/PD target.
What is the avibactam PK/PD target?
Studies used 50% fT > 2.5 mg/L as the avibactam target for aztreonam-avibactam PK/PD analyses.
Does renal impairment affect aztreonam-avibactam pharmacokinetics?
Yes. Because both components undergo substantial renal elimination, reduced renal function can alter drug exposure. Renal-adjusted dosing is therefore addressed in prescribing information.
Why is aztreonam-avibactam given by prolonged infusion?
The regimen uses prolonged IV infusion as part of an exposure strategy for this time-dependent antibacterial combination. The U.S. prescribing information specifies a 3-hour infusion for the approved regimen.
Does PK/PD target attainment guarantee clinical success?
No. PK/PD target attainment supports dose selection and pharmacological activity but does not guarantee clinical cure. Patient factors, infection site, organism susceptibility and other clinical variables also influence outcomes.
Conclusion
Aztreonam avibactam pharmacokinetics provides an important bridge between the drug’s concentration-time profile and its antibacterial activity.
Both aztreonam and avibactam have relatively short terminal half-lives and are substantially eliminated through the kidneys. This makes renal function an important determinant of exposure. Current PK/PD development has focused on achieving appropriate exposure for both components, with aztreonam activity associated with time above MIC and avibactam activity associated with time above a defined threshold concentration.
The 2026 Phase 1 study adds contemporary clinical pharmacology data and found broadly consistent exposure characteristics compared with previous studies.
Ultimately, PK/PD evidence helps explain why a particular dosing strategy is designed the way it is, but it should be interpreted alongside susceptibility testing, clinical evidence and patient-specific factors.